Page 4 - ஜென்னர் நிறுவனம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Africa.com Headlines / July 30, 2021 July 29, 2021 / 4 minutes of reading The RBM Partnership to End Malaria welcomes the announcement today of a major project by kENUP Foundation and BioNTech to develop the first mRNA-based prophylactic malaria vaccine. Supported by the World Health Organization (WHO), the Africa Centres for Disease Control and Prevention, the European Commission and European Investment Bank, and international partners, the project aims to use mRNA technology as part of an initiative aimed at expanding vaccine development for, and manufacturing capacity across Africa, to fight malaria, a disease that ravages the continent each year. Welcoming the news,  Dr Abdourahmane Diallo, CEO of the RBM Partnership to End Malaria, commented: “Today’s announcement to develop an mRNA-based, highly effective preventative malaria vaccine to protect people of all ages marks a major step toward developing game-changing technology for malaria eradication. The malaria figh

Burkina fasoAbdourahmane dialloWorld health organizationEuropean commissionUniversity of oxford jenner instituteEnup foundationEuropean investment bankPartnership to end malariaEnd malariaAfrica centresDisease controlJenner instituteபுர்கினா ஃபாஸொஉலகம் ஆரோக்கியம் ஆர்கநைஸேஶந்ஐரோப்பிய தரகுபல்கலைக்கழகம் ஆஃப் ஆக்ஸ்ஃபர்ட் ஜென்னர் நிறுவனம்